Q1 Earnings Estimate for BCRX Issued By Wedbush

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at Wedbush issued their Q1 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, February 25th. Wedbush analyst L. Chico forecasts that the biotechnology company will earn ($0.06) per share for the quarter. Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.15 EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.69 EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.09 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the firm posted $0.28 EPS. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on the stock. Evercore ISI raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Trading Up 1.7 %

NASDAQ BCRX opened at $8.61 on Thursday. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -14.11 and a beta of 1.75. The company’s 50 day moving average is $8.09 and its two-hundred day moving average is $7.85.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Xponance Inc. boosted its stake in BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after buying an additional 1,242 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the period. Sei Investments Co. boosted its stake in shares of BioCryst Pharmaceuticals by 2.8% during the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 1,537 shares during the period. Captrust Financial Advisors boosted its stake in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,644 shares during the period. Finally, Creative Planning boosted its stake in shares of BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after purchasing an additional 2,734 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.